Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 4/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681937 | 0.93 | USP2 (0.58) | NPC1RAB9AKDM4EPOLBUSP2 | |
| SCHEMBL21712335 | 0.89 | KDM4E (0.60) | NPC1RAB9AKDM4EPOLBUSP2 | |
| SCHEMBL6042440 | 0.85 | POLB (0.68) | KDM4EPOLBUSP2L3MBTL1CNR1 | |
| SCHEMBL21681926 | 0.83 | POLB (0.62) | NPC1RAB9AKDM4EPOLBCNR1 | |
| SCHEMBL19859004 | 0.83 | TSHR (0.68) | KDM4EPOLBKMOPRKAB2PRKAG1 | |
| SCHEMBL21730049 | 0.80 | NPC1 (0.61) | NPC1RAB9AKDM4EPOLBUSP2 | |
| SCHEMBL11898739 | 0.79 | NPC1 (0.97) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1319360 | 0.79 | NPC1 (0.54) | NPC1RAB9AKDM4EPRKAB2PRKAG1 | |
| SCHEMBL13205904 | 0.79 | NPC1 (0.49) | NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL3454630 | 0.79 | USP2 (0.67) | KDM4EPOLBUSP2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| WO-2020036812-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036574-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I' PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036812-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20200055871-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-02-20 | — | — | US | disclosed |
| US-20200055871-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-02-20 | — | — | US | disclosed |
| WO-2020033782-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033782-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055871-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | NPC1 3269/4885RAB9A 1570/4885KDM4E 4380/4885 |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | NPC1 3269/4885RAB9A 1570/4885KDM4E 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.